Equities research analysts at StockNews.com began coverage on shares of Catalent (NYSE:CTLT – Get Free Report) in a report issued on Sunday. The brokerage set a “hold” rating on the stock. Other ...

The market is driven by rising prevalence of several chronic disorders, rising focus on regenerative medicines, and increased federal investment in stem cell therapy.

Role of Real-World Evidence (RWE) in Driving Pharmaceutical R&D Outsourcing Market Growth ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk shares fell nearly 30% in the fourth quarter on disappointing clinical trial data, and other concerns. Bank of ...

After holding leadership positions at contract manufacturers Patheon and Thermo Fisher Scientific, working in the food and ...

Healthcare proved to be a resilient market for mergers and acquisitions in 2024, despite deal volume declining 9% from 2023. ...

The "Semaglutides Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This Semaglutides market report covers market characteristics, size and growth, segmentation, regional ...

Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have been given an average rating of “Hold” by the seven analysts that are presently covering the company, Marketbeat.com reports. Seven analysts ...

Heating and air-conditioning equipment maker Lennox International Inc. is replacing contract drug maker Catalent Inc. in the S&P 500, S&P Dow Jones Indices said late Wednesday. Novo Nordisk’s ...